Multiple genes for neuropeptides and their receptors: co-evolution and physiology

被引:51
作者
Darlison, MG [1 ]
Richter, D [1 ]
机构
[1] Univ Hamburg, Klinikum Eppendorf, Inst Zellbiochem & Klin Neurobiol, D-20246 Hamburg, Germany
关键词
D O I
10.1016/S0166-2236(98)01333-2
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
It is now well established that neuropeptide receptors, which are present throughout the CNS and in peripheral tissues, frequently exist in a variety of different forms (called subtypes), each of which is encoded by a distinct gene,With the recent identification of new neuropeptide genes, it has become clear that families of neuropeptides also occur, which raises the possibility that specific peptide ligands activate particular receptor subtypes preferentially,This article reviews some of the recent advances in the neuropeptide field and provides evidence in support of three ideas: (1) that different receptor subtypes for a given ligand can be distinguished physiologically; (2) that neuropeptide genes probably arose before the corresponding receptor genes; and (3) that, despite the current wealth of information on neuropeptides and neuropeptide receptors, several new members are likely to be discovered before the beginning of the next millennium.
引用
收藏
页码:81 / 88
页数:8
相关论文
共 74 条
[1]  
Acher R, 1995, ADV EXP MED BIOL, V395, P615
[2]   Structural bases of vasopressin/oxytocin receptor function [J].
Barberis, C ;
Mouillac, B ;
Durroux, T .
JOURNAL OF ENDOCRINOLOGY, 1998, 156 (02) :223-229
[3]  
BARNARD EA, 1993, NEUROTRANSMITTER REC, P297
[4]   Nonpeptide antagonists of neuropeptide receptors: tools for research and therapy [J].
Betancur, C ;
Azzi, M ;
Rostene, W .
TRENDS IN PHARMACOLOGICAL SCIENCES, 1997, 18 (10) :372-386
[5]   Effects of chronic administration of 7-benzylidene-7-dehydronaltrexone and naltriben on the antinociceptive actions of delta(1)- and delta(2)-opioid receptor agonists [J].
Bhargava, HN ;
Zhao, GM ;
House, RV ;
Thomas, PT .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1996, 311 (2-3) :127-132
[6]   Y-receptor subtypes - How many more? [J].
Blomqvist, AG ;
Herzog, H .
TRENDS IN NEUROSCIENCES, 1997, 20 (07) :294-298
[7]  
BLUMER KJ, 1988, J BIOL CHEM, V263, P10836
[8]   Molecular neurobiology and pharmacology of the vasopressin oxytocin receptor family [J].
Burbach, JPH ;
Adan, RAH ;
Lolait, SJ ;
vanLeeuwen, FW ;
Mezey, E ;
Palkovits, M ;
Barberis, C .
CELLULAR AND MOLECULAR NEUROBIOLOGY, 1995, 15 (05) :573-595
[9]   Corticotrophin-releasing factor receptors: From molecular biology to drug design [J].
Chalmers, DT ;
Lovenberg, TW ;
Grigoriadis, DE ;
Behan, DP ;
DeSouza, EB .
TRENDS IN PHARMACOLOGICAL SCIENCES, 1996, 17 (04) :166-172
[10]   TYR115 IS THE KEY RESIDUE FOR DETERMINING AGONIST SELECTIVITY IN THE V1A VASOPRESSIN RECEPTOR [J].
CHINI, B ;
MOUILLAC, B ;
ALA, Y ;
BALESTRE, MN ;
TRUMPPKALLMEYER, S ;
HOFLACK, J ;
ELANDS, J ;
HIBERT, M ;
MANNING, M ;
JARD, S ;
BARBERIS, C .
EMBO JOURNAL, 1995, 14 (10) :2176-2182